The desmoplastic T-cell exclusion translates to clinical effects, with distinct pancreatic cancer patient subpopulations with high juxtatumoral densities of CD8+ T-cells having longer survival times than patients with low densities [491]. This evidence concerns the gene CD8A and familial pancreatic carcinoma.